Vivoryon Therapeutics N.V. successfully raises EUR 5.1 million through a private placement, issuing 3,380,500 new shares at EUR 1.50 each. This capital increase is supported by both existing and new shareholders, extending the company’s cash runway into Q3 2026. The proceeds will be used to secure a strategic partnership for varoglutamstat in chronic kidney disease. Vivoryon is currently in discussions with pharmaceutical companies for collaboration. The company expects the cash and cash equivalents, along with the private placement proceeds, to fund operations until Q3 2026. The new shares are set to be admitted to trading on Euronext Amsterdam on October 7, 2025.

Read more at GlobeNewswire: Vivoryon Therapeutics N.V. Successfully Completes Private